Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Uveitis, Intermediate: later-stage trial registry

1 of 6 indexed Uveitis, Intermediate trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Uveitis, Intermediate: 6 US clinical trials tracked, 1 recruiting.

Uveitis, Intermediate is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Clearside Biomedical, running 3 of these trials.

Enrollment posture brief

Registry condition uveitis-intermediate

OPEN 1 | RECR 17% | LATE 4 | EARLY 1 | RANK #2866 | SPON 3

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Uveitis, Intermediate (this)17%
Open-enrollment share among volume-matched conditions near Uveitis, Intermediate

Uveitis, Intermediate lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Uveitis, Intermediate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Uveitis, Intermediate is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Uveitis, Intermediate research.

    Clearside Biomedical accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Uveitis, Intermediate enrolment sits around 160 participants.

    Median target enrolment is 160 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Uveitis, Intermediate research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 34

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4

Top Sponsors

Named interventions

Most-linked intervention names on Uveitis, Intermediate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

0.8 mg CLS-TA Drug
1 trials
4 mg CLS-TA Drug
1 trials
LX211 Drug
1 trials
4 mg CLS-TA Suprachoriodal Injection Drug
1 trials
4mg CLS-TA Suprachoriodal Injection Drug
1 trials
Sham Procedure Drug
1 trials
Placebo PO QD Drug
1 trials
Brepocitinib PO QD Drug
1 trials

US sites by state

Facility locations filed on Uveitis, Intermediate trials. A trial with sites in several states counts in each.

Texas 4 trials
Massachusetts 4 trials
Illinois 4 trials
Florida 4 trials
Arizona 4 trials
Maryland 3 trials
Indiana 3 trials
Georgia 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Uveitis, Intermediate page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uveitis, Intermediate condition card totals 6 registered trials; most-linked intervention 0.8 mg CLS-TA; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.